4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006.

  • Long G
  • Schachter J
  • Ribas A
  • et al.
N/ACitations
Citations of this article
41Readers
Mendeley users who have this article in their library.
Get full text

Abstract

9503Background: KEYNOTE-006 (NCT01866319) established superiority of pembro over ipi in advanced melanoma. We provide 4-y outcomes, long-term data for pts who completed 2 y pembro, and data for second course. Methods: Eligible pts (N = 834) were randomly assigned 1:1:1 to receive pembro 10 mg/kg Q2W, pembro 10 mg/kg Q3W, or ipi 3 mg/kg Q3W for 4 doses. Treatment was continued for 2 y (pembro only; completed defined as ≥94 weeks of pembro and discontinued with at least SD) or until disease progression, intolerable toxicity, or pt/investigator decision to discontinue. End points were OS and ORR per irRC by investigator review. Upon PD, eligible pts could receive an additional 1 y pembro. Results: At data cutoff (Dec 4, 2017), median follow-up was 45.9 mo (range, 0.3-50.0). 4-y OS rate was 42\% in the pooled pembro arms (n = 556) and 34\% in the ipi arm (n = 278); ORR was 42\% and 17\%. Median DOR was NR for pembro (range, 1.0+ to 46.1+ mo) or ipi (1.1+ to 45.6+ mo); 62\% pembro- and 59\% ipi-treated pts had a response lasting ≥42 mo. In treatment-naive pts, 4-y OS rates were 44\% in the pooled pembro arms (n = 368) and 36\% in the ipi arm (n = 181); ORR was 47\% and 17\%. Median DOR was NR for pembro (range, 1.6+ to 46.0+ mo) or ipi (1.1+ to 42.2+ mo); 65\% pembro- and 68\% ipi-treated pts had a response lasting ≥42 mo. Of 556 pts, 103 (19\%) completed the protocol-specified 2-y pembro (28 CR, 65 PR, 10 SD). Median follow-up was 20.3 mo after pembro completion; 89 (86\%) pts did not progress and 14 pts had PD (prior response 2 CR, 9 PR, 3 SD). Eight pts (prior response 3 CR [including 1 pt who discontinued early with CR and then progressed], 4 PR, and 1 SD) received second-course pembro but 3 discontinued (1 each due to PD, interstitial pneumonia, and infection). Median duration of second-course pembro was 9.7 mo; BOR was 1 CR, 1 PR, 5 SD, and 1 PD. 1 pt with SD had subsequent PD. 5 pts had a TRAE during second-course pembro; there were no grade 3/4 TRAEs or deaths. Conclusions: Pembro provides durable antitumor activity in treatment-naive or -experienced pts with advanced melanoma. Of pts who completed 2 y pembro, 86\% were progression free at 20 mo. Pembro is safe and provides additional antitumor activity as second-course treatment. Clinical trial information: NCT01866319.

Cite

CITATION STYLE

APA

Long, G. V., Schachter, J., Ribas, A., Arance, A. M., Grob, J.-J., Mortier, L., … Robert, C. (2018). 4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006. Journal of Clinical Oncology, 36(15_suppl), 9503–9503. https://doi.org/10.1200/jco.2018.36.15_suppl.9503

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free